Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases

Recombinant activated factor VII (rFVIIa) is the bypassing agent used in the first-line hemostatic therapy for acquired hemophilia A (AHA); however, the occurrence of thrombotic complications in rFVIIa-treated AHA patients was recently reported to be 2.9–6.5%. Therefore, the investigation of the pro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Gen Med
Main Authors: Saito, Makoto, Kanaya, Minoru, Izumiyama, Koh, Mori, Akio, Irie, Tatsuro, Tanaka, Masanori, Morioka, Masanobu, Ieko, Masahiro
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2016
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098745/
https://ncbi.nlm.nih.gov/pubmed/27843336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJGM.S118422
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares